title: Current Treatment Options in Raynaud's Phenomenon.
abstract: The treatment of Raynaud's phenomenon (RP) strictly depends on the severity of symptoms and on the presence of an underlying systemic disease. For this reason, any patient with RP should be carefully assessed for signs and symptoms that may herald an underlying disease. Primary RP can usually be managed with conservative nonpharmacologic lifestyle modifications (eg, avoidance of cold temperatures, tobacco, caffeine, and any drug interfering with vascular tone) and pharmacologic treatment added only if attacks are poorly controlled. Vasodilating drugs (eg, calcium channel blockers, angiotensin II receptor antagonists, topical nitrates, and prostanoids) are still the mainstay of medical therapy for RP. Anecdotal reports with different kinds of therapies appear regularly but always need evidence-based confirmation. In particular, antioxidant agents may be useful in limiting the progressive endothelial damage. Novel therapeutic tools interfering either with primary or secondary pathogenetic processes (ie, endothelial and peripheral nervous system dysfunction and smooth muscle cell hypertrophy) are awaited.
authors.affiliation: Section of Rheumatology, Department of Internal Medicine, University of Florence, Viale Pieraccini, 18-50139 Florence, Italy. generini@hotmail.com
authors.forename: Sergio
authors.initials: S
authors.lastname: Generini
authors.forename: Angela
authors.initials: A
authors.lastname: Del Rosso
authors.forename: Alberto
authors.initials: A
authors.lastname: Pignone
authors.forename: Marco
authors.initials: M
authors.lastname: Matucci Cerinic